Avacta Group PLC New Facilities in Cambridge and Wetherby
August 16 2016 - 2:01AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
16 August 2016
Avacta expands into new facilities in Cambridge and Wetherby
Expansion provides significant increase in laboratory space
Wetherby and Cambridge, UK, 16(th) August 2016: Avacta Group plc
(AIM: AVCT) ("Avacta" or "the Group"), the developer of Affimer(R)
biotherapeutics and research reagents, today announced it has
opened two new facilities, in Cambridge and Wetherby, Yorkshire.
The new buildings almost double the Company's overall footprint,
which increases from 9,500 to 18,500 sq ft, including new
state-of-the-art laboratory facilities.
The new laboratories and office space have been established to
allow for operations at both sites to expand to meet increasing
commercial demands and accommodate Avacta's growing R&D
programme.
The new Cambridge site is located on the Lion Works Business
Park in Whittlesford, and covers 5,500 sq ft, of which 70% houses
laboratories. In Wetherby, the Thorp Arch Estate has provided a new
13,000 sq ft building which Avacta has fitted with offices and
laboratories accommodating around 60 FTEs.
Dr Alastair Smith, Chief Executive Officer, Avacta, said: "I am
delighted with the new labs that the Company now has in place in
Wetherby and Cambridge. The teams will be working in truly world
class facilities that will also help in attracting talented new
staff and will present the Company well to potential customers and
partners."
ENDS
Notes to Editors
For high resolution images please contact
katie.odgaard@zymecommunications.com
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
Numis Securities Limited Tel: +44 (0)
Michael Meade / Freddie Barnfield 207 260 1000
- Nominated Adviser www.numiscorp.com
James Black - Corporate Broking
WG Partners Tel: +44 (0)
David Wilson 203 705 9318
Nigel Barnes Tel: +44 (0)
Claes Spang 203 705 9217
www.wgpartners.co.uk
Zyme Communications (Trade and Tel: +44 (0)7787
Regional Media) 502 947
Katie Odgaard katie.odgaard@zymecommunications.com
FTI Consulting (Financial Media Tel: +44 (0)
and IR) 203 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $75bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of targets to enable diagnostics, research assays
and therapeutics.
Avacta has a pre-clinical therapeutic development programme with
an in-house focus on immuno-oncology and bleeding disorders as well
as partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADDGDIUGBBGLU
(END) Dow Jones Newswires
August 16, 2016 02:01 ET (06:01 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024
